Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
- Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
- The AACR will take place in San Diego, California, USA, from April 5 to 10, 2024.
- The abstract will be available on the AACR website April 5, 2024, at 3:00 p.m.
- Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024.